# Supportive Care & Survivorship

Source: https://onco.cc/fronts/supportive-care/  
OnCo record `supportive-care` (Front). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Supportive care and survivorship covers everything that keeps a patient well enough to receive treatment, and well afterwards.

## Summary

Supportive care and survivorship covers everything that keeps a patient well enough to receive treatment and well afterwards: anti-emetics, growth factors, scalp cooling, cardio-oncology, fertility preservation, geriatric assessment, palliative integration, exercise oncology, financial toxicity mitigation and survivorship monitoring, an area under-studied relative to its impact. It also houses the complementary approaches people ask about, from acupuncture, CBT for fatigue and music therapy to ginger, curcumin, melatonin, medicinal mushrooms, homeopathy and the so-called herbal cancer cures. Scalp cooling, cardio-oncology, exercise oncology, geriatric assessment, head and neck and thyroid cancer, and companies such as Cancer Commons link here.

## Fields

- Kind: Front
- Last checked: 2026-09-04

## Sources

- NCI: Side effects of cancer treatment: https://www.cancer.gov/about-cancer/treatment/side-effects
- NCI: Survivorship: https://www.cancer.gov/about-cancer/coping/survivorship

## Connected records

- technologies: [A changed face and voice: body image after head and neck cancer treatment](https://onco.cc/technologies/rejuv-mind-visible-difference-head-and-neck/), [Active surveillance of papillary microcarcinoma](https://onco.cc/technologies/active-surveillance-thyroid/), [Acupuncture and acupressure for chemotherapy nausea](https://onco.cc/technologies/acupuncture-nausea/), [Acupuncture for aromatase-inhibitor joint pain](https://onco.cc/technologies/acupuncture-aromatase-inhibitor-arthralgia/), [Acupuncture for chemotherapy-induced neuropathy](https://onco.cc/technologies/acupuncture-chemotherapy-neuropathy/), [Acupuncture for dry mouth after head and neck radiotherapy](https://onco.cc/technologies/acupuncture-xerostomia/), [Acupuncture for hot flushes on endocrine therapy](https://onco.cc/technologies/acupuncture-hot-flushes/), [ADC payload neutralisers](https://onco.cc/technologies/adc-payload-neutralizer/), [Adolescents and young adults: a group with its own cancers, its own gap and its own needs](https://onco.cc/technologies/rejuv-ayac-distinct-group/), [After a transplant or cell therapy: what to ask for](https://onco.cc/technologies/rejuv-tx-what-to-ask-for/), [After ruxolitinib: belumosudil, axatilimab and ibrutinib in chronic GvHD](https://onco.cc/technologies/gvhd-belumosudil-axatilimab-ibrutinib/), [After treatment in Australia: a stated model of survivorship care](https://onco.cc/technologies/rejuv-access-survivorship-care-australia/), [After treatment in Germany: a rehabilitation entitlement, not a leaflet](https://onco.cc/technologies/rejuv-access-survivorship-care-germany/), [After treatment in low and middle income countries: mostly nothing](https://onco.cc/technologies/rejuv-access-survivorship-care-lmic/), [After treatment in the Nordic countries: rehabilitation written into the pathway](https://onco.cc/technologies/rejuv-access-survivorship-care-nordic/), [After treatment in the UK: personalised care, and follow-up you lead yourself](https://onco.cc/technologies/rejuv-access-survivorship-care-uk/), [After treatment in the United States: the survivorship care plan, and what the trial found](https://onco.cc/technologies/rejuv-access-survivorship-care-us/), [Alternative medicine used instead of standard treatment](https://onco.cc/technologies/alternative-medicine-instead-of-treatment/), [American ginseng for cancer-related fatigue](https://onco.cc/technologies/american-ginseng-fatigue/), [Antiandrogens for hair: spironolactone, finasteride, dutasteride](https://onco.cc/technologies/hair-antiandrogens-alopecia/), [Antiemetics for chemotherapy-induced nausea and vomiting](https://onco.cc/technologies/antiemetic-therapy/), [Antineoplastons (Burzynski clinic)](https://onco.cc/technologies/antineoplastons/), [Anxiety after cancer, in survivors and in their partners](https://onco.cc/technologies/rejuv-mind-anxiety-after-cancer/), [Anxiety around scans, and what the evidence says about how often to scan](https://onco.cc/technologies/rejuv-mind-scan-anxiety/), [Aromatherapy](https://onco.cc/technologies/aromatherapy-cancer/), [Asking people how they are, every week, as a treatment in its own right](https://onco.cc/technologies/rejuv-measure-epro-as-treatment/), [Ayurvedic medicine and cancer](https://onco.cc/technologies/ayurvedic-medicine-cancer/), [B-cell aplasia and low antibodies after CAR-T and bispecifics, and immunoglobulin replacement](https://onco.cc/technologies/rejuv-tx-b-cell-aplasia-and-immunoglobulin/), [Balance, dizziness and falls after cancer treatment](https://onco.cc/technologies/rejuv-rehab-balance-vestibular/), [Biliary stenting and drainage](https://onco.cc/technologies/biliary-stenting-drainage/), [Bimatoprost for eyelash and eyebrow regrowth](https://onco.cc/technologies/bimatoprost-eyelash-regrowth/), [Biosimilar manufacturing and comparability](https://onco.cc/technologies/biosimilar-manufacturing/), [Black salve and other escharotic pastes](https://onco.cc/technologies/black-salve-escharotics/), [Blood counts that do not come back after CAR-T: ICAHT](https://onco.cc/technologies/rejuv-tx-prolonged-cytopenias/), [Body image after cancer treatment: how it is measured, what drives it, and what helps](https://onco.cc/technologies/rejuv-mind-body-image-after-cancer/), [Bone after childhood cancer: peak bone mass, osteonecrosis and what rebuilds](https://onco.cc/technologies/rejuv-paed-bone/), [Bone loss caused by cancer treatment, and what rebuilds it](https://onco.cc/technologies/cancer-treatment-bone-loss/), [Bone-modifying agents (bisphosphonates, denosumab)](https://onco.cc/technologies/bone-modifying-agents/), [Bone, eyes, kidneys and lungs after transplant](https://onco.cc/technologies/rejuv-tx-bone-eyes-kidneys-lungs/), [Bowel function after pelvic radiotherapy](https://onco.cc/technologies/bowel-after-pelvic-radiotherapy/), [Breast cancer after chest radiotherapy in childhood, and the screening that follows](https://onco.cc/technologies/rejuv-paed-breast-after-chest-radiotherapy/), [BREAST-Q and the Q-portfolio: measuring what an operation left behind](https://onco.cc/technologies/rejuv-measure-breast-q/), [Breathing and exercise capacity after lung resection](https://onco.cc/technologies/rejuv-rehab-respiratory/), [Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine](https://onco.cc/technologies/cachexia-appetite-pharmacotherapy/), [Cachexia-directed therapy (GDF-15 blockade)](https://onco.cc/technologies/cachexia-therapy/), [Camouflage and restoration: fibres, micropigmentation, transplantation](https://onco.cc/technologies/hair-camouflage-and-restoration/), [Cancer neuroscience: cutting the nerve supply](https://onco.cc/technologies/nerve-tumour-denervation/), [Cancer pain management](https://onco.cc/technologies/pain-management/), [Cancer rehabilitation: the discipline that puts function back](https://onco.cc/technologies/rejuv-rehab-cancer-rehabilitation/), [Cancer-associated thrombosis prevention and treatment](https://onco.cc/technologies/cancer-associated-thrombosis/), [Cannabinoids for chemotherapy nausea (dronabinol, nabilone, medical cannabis)](https://onco.cc/technologies/cannabinoids-nausea/), [Cannabis and cannabinoids for pain, appetite and cancer control](https://onco.cc/technologies/cannabinoids-pain-appetite/), [Cardio-oncology](https://onco.cc/technologies/cardio-oncology/), [Cardiopulmonary exercise testing: the hardest number in recovery](https://onco.cc/technologies/rejuv-measure-cardiopulmonary-exercise-testing/), [Children of a parent treated for cancer](https://onco.cc/technologies/rejuv-life-children-of-a-parent-with-cancer/), [Chronic graft-versus-host disease](https://onco.cc/technologies/gvhd-chronic-overview/), [Chronic GvHD organ by organ: skin, mouth, eyes, gut, liver, joints and genital tract](https://onco.cc/technologies/gvhd-organ-by-organ/), [Chronotherapy: timing treatment to the body clock](https://onco.cc/technologies/chronotherapy/), [Clinical hypnosis for procedures, pain and hot flushes](https://onco.cc/technologies/hypnosis-cancer-care/), [Clonal haematopoiesis after cancer treatment](https://onco.cc/technologies/rejuv-age-clonal-haematopoiesis-after-therapy/), [Closed-system transfer devices for hazardous drugs (PhaSeal, ChemoLock, Equashield)](https://onco.cc/technologies/closed-system-transfer-devices/), [Cognitive behavioural therapy for fatigue and distress](https://onco.cc/technologies/cbt-fatigue-distress/), [Cognitive behavioural therapy for insomnia (CBT-I)](https://onco.cc/technologies/cbt-insomnia-cancer/), [Community oncology and site networks](https://onco.cc/technologies/community-oncology-networks/), [Compounded hormone pellets](https://onco.cc/technologies/rejuv-frontier-hormone-pellets/), [Compression, decongestive therapy and exercise for lymphoedema](https://onco.cc/technologies/lymphoedema-decongestive-therapy/), [Creams and lotions tried to prevent chemotherapy hair loss](https://onco.cc/technologies/hair-topical-prevention-agents/), [CT body composition and sarcopenia measurement](https://onco.cc/technologies/ct-body-composition-sarcopenia/), [Curcumin and turmeric](https://onco.cc/technologies/curcumin-turmeric/), [Dance and movement therapy](https://onco.cc/technologies/dance-movement-therapy/), [Decentralised and hybrid clinical trials](https://onco.cc/technologies/decentralised-clinical-trials/), [Depression during and after cancer: the interview-based prevalence, and the care model that works](https://onco.cc/technologies/rejuv-mind-depression-after-cancer/), [Dietary supplements during cancer treatment: interactions and harms](https://onco.cc/technologies/dietary-supplements-treatment-interactions/), [Dietitian-led weight-loss programmes in HR-positive breast cancer](https://onco.cc/technologies/dietitian-led-weight-loss-breast/), [DPYD genotyping and DPD phenotyping before fluoropyrimidines](https://onco.cc/technologies/dpyd-genotyping/), [Dry mouth, teeth and taste after head and neck radiotherapy](https://onco.cc/technologies/dry-mouth-teeth-after-head-neck-radiotherapy/), [Early integrated palliative care](https://onco.cc/technologies/palliative-care/), [Education, work and the years that were interrupted](https://onco.cc/technologies/rejuv-ayac-education-and-work/), [Electronic patient-reported outcome (ePRO) symptom monitoring](https://onco.cc/technologies/epro-symptom-monitoring/), [Electronic patient-reported outcomes and remote monitoring](https://onco.cc/technologies/remote-patient-monitoring/), [Employment rights with cancer in the United Kingdom](https://onco.cc/technologies/rejuv-life-employment-rights-uk/), [Employment rights with cancer in the United States](https://onco.cc/technologies/rejuv-life-employment-rights-us/), [Enhanced recovery (ERAS) and perioperative nutrition](https://onco.cc/technologies/eras-perioperative-nutrition/), [Enteral and parenteral nutrition support](https://onco.cc/technologies/enteral-parenteral-nutrition/), [EORTC QLQ-C30: the questionnaire most cancer trials use](https://onco.cc/technologies/rejuv-measure-eortc-qlq-c30/), [Epigenetic age after cancer treatment](https://onco.cc/technologies/rejuv-age-epigenetic-clocks/), [EQ-5D: health reduced to one number, and what that number is for](https://onco.cc/technologies/rejuv-measure-eq-5d/), [Essiac, Hoxsey and other 'herbal cancer cures'](https://onco.cc/technologies/essiac-herbal-cancer-cures/), [Evidence-based integrative oncology](https://onco.cc/technologies/integrative-oncology/), [Exercise & lifestyle oncology](https://onco.cc/technologies/exercise-oncology/), [Exercise during chemotherapy and radiotherapy](https://onco.cc/technologies/exercise-during-chemotherapy/), [Exercise is the best-evidenced thing on this front, and most survivors are not doing it](https://onco.cc/technologies/rejuv-access-exercise-programmes/), [Exosome injections](https://onco.cc/technologies/rejuv-frontier-exosome-injections/), [Extracorporeal photopheresis for graft-versus-host disease](https://onco.cc/technologies/gvhd-photopheresis/), [FACT-G and the FACIT family: the other main questionnaire](https://onco.cc/technologies/rejuv-measure-fact-and-facit/), [Fat grafting after cancer surgery](https://onco.cc/technologies/rejuv-frontier-fat-grafting/), [Fatigue after cancer treatment: what actually works](https://onco.cc/technologies/cancer-related-fatigue-management/), [Fear that the cancer will come back: how common it is, and when it stops being ordinary worry](https://onco.cc/technologies/rejuv-mind-fear-of-recurrence/), [Fenbendazole, ivermectin and other internet 'repurposed cures'](https://onco.cc/technologies/fenbendazole-ivermectin-repurposing-claims/), [Fertility in boys and young men treated for cancer, including testicular tissue banking](https://onco.cc/technologies/rejuv-paed-fertility-male/), [Fertility in girls and young women treated for cancer, including ovarian tissue freezing](https://onco.cc/technologies/rejuv-paed-fertility-female/), [Fertility, growth and what total body irradiation costs](https://onco.cc/technologies/rejuv-tx-fertility-and-growth/), [Financial toxicity and financial navigation](https://onco.cc/technologies/financial-navigation/), [Fish oil (EPA) for cancer weight loss](https://onco.cc/technologies/omega3-epa-cachexia/), [Frailty and late effects in survivors](https://onco.cc/technologies/rejuv-age-frailty-and-late-effects/), [Frozen gloves, socks and compression for taxane nail and nerve damage](https://onco.cc/technologies/frozen-gloves-compression-taxane/), [G8 geriatric screening tool](https://onco.cc/technologies/g8-geriatric-screening/), [Generic oncology drug supply and shortage mitigation](https://onco.cc/technologies/generic-drug-shortage-response/), [Generic sterile injectables (the 2023 platinum shortage)](https://onco.cc/technologies/sterile-injectable-generics-manufacturing/), [Geriatric assessment](https://onco.cc/technologies/geriatric-assessment/), [Gerson therapy, coffee enemas and 'detox' regimens](https://onco.cc/technologies/gerson-therapy-detox-regimens/), [Getting psychological help after cancer: the stepped-care model, and what is actually commissioned](https://onco.cc/technologies/rejuv-mind-access-to-psychological-care/), [Ginger for chemotherapy nausea](https://onco.cc/technologies/ginger-nausea/), [Global oncology and access in low- and middle-income countries](https://onco.cc/technologies/global-oncology-access/), [Glutamine for mucositis and neuropathy](https://onco.cc/technologies/glutamine-mucositis-neuropathy/), [Going back to driving, lifting and exercise](https://onco.cc/technologies/rejuv-rehab-driving-and-exercise-return/), [Going back to work after cancer: the rates, and the programmes that change them](https://onco.cc/technologies/rejuv-life-return-to-work/), [Green tea and EGCG extracts](https://onco.cc/technologies/green-tea-egcg/), [Growth and final height after treatment in childhood, and growth hormone](https://onco.cc/technologies/rejuv-paed-growth-and-height/), [Growth factors: G-CSF and febrile neutropenia prevention](https://onco.cc/technologies/g-csf-growth-factors/), [Hearing after platinum and cranial radiotherapy in a developing child](https://onco.cc/technologies/rejuv-paed-hearing/), [Hearing and tinnitus after platinum chemotherapy](https://onco.cc/technologies/hearing-after-platinum-chemotherapy/), [Heart function after anthracyclines, trastuzumab and chest radiotherapy](https://onco.cc/technologies/cardiotoxicity-surveillance-recovery/), [High-dose intravenous vitamin C](https://onco.cc/technologies/high-dose-vitamin-c/), [Homeopathy](https://onco.cc/technologies/homeopathy-cancer/), [Honey for radiation mucositis](https://onco.cc/technologies/honey-radiation-mucositis/), [Hormones, metabolism and the heart after transplant](https://onco.cc/technologies/rejuv-tx-endocrine-and-cardiometabolic/), [Hospice and end-of-life care](https://onco.cc/technologies/hospice-end-of-life/), [How chronic GvHD is diagnosed and scored: the NIH consensus criteria](https://onco.cc/technologies/gvhd-nih-consensus-criteria/), [How long it takes to diagnose cancer in a young person, and what the evidence actually says](https://onco.cc/technologies/rejuv-ayac-diagnostic-delay/), [How much illness childhood cancer survivors carry, and at what age](https://onco.cc/technologies/rejuv-paed-chronic-disease-burden/), [How recovery is measured: the questionnaires behind the numbers](https://onco.cc/technologies/rejuv-measure-patient-reported-outcomes/), [Hydrazine sulfate](https://onco.cc/technologies/hydrazine-sulfate/), [Hyperbaric oxygen for late radiation injury](https://onco.cc/technologies/hyperbaric-oxygen-radiation-injury/), [Hyperbaric oxygen sold as rejuvenation](https://onco.cc/technologies/rejuv-frontier-hyperbaric-oxygen-claims/), [ICANS, and whether thinking recovers after CAR-T](https://onco.cc/technologies/rejuv-tx-icans-and-neurocognition/), [Immune endocrine damage is usually permanent, and almost nobody is told](https://onco.cc/technologies/rejuv-recovery-endocrine-permanence/), [Infection risk after transplant and cell therapy, phase by phase, and the prophylaxis that follows it](https://onco.cc/technologies/rejuv-tx-infection-by-phase/), [Infusion pumps, ports, and ambulatory chemotherapy devices](https://onco.cc/technologies/infusion-devices-vascular-access/), [Insurance, mortgages and the right to be forgotten](https://onco.cc/technologies/rejuv-life-insurance-loans-and-the-right-to-be-forgotten/), [Intravenous NAD+ drips](https://onco.cc/technologies/rejuv-frontier-nad-infusions/), [Iron overload after transplant](https://onco.cc/technologies/rejuv-tx-iron-overload/), [Kidneys after cisplatin, ifosfamide, radiotherapy and nephrectomy in childhood](https://onco.cc/technologies/rejuv-paed-kidneys/), [Laetrile (amygdalin, 'vitamin B17')](https://onco.cc/technologies/laetrile-amygdalin/), [Late deaths after childhood cancer, what causes them, and the proof that gentler treatment worked](https://onco.cc/technologies/rejuv-paed-late-mortality/), [Late effects after a stem cell transplant](https://onco.cc/technologies/rejuv-tx-late-effects-overview/), [Living with a stoma, and living after an amputation](https://onco.cc/technologies/rejuv-mind-body-after-stoma-and-limb-loss/), [Long-term follow-up for gene-modified cell products: fifteen years, and why](https://onco.cc/technologies/rejuv-tx-gene-modified-follow-up/), [Long-term follow-up in the United Kingdom: what a survivor is actually offered](https://onco.cc/technologies/rejuv-paed-uk-long-term-follow-up/), [Low-level light therapy (photobiomodulation) for hair](https://onco.cc/technologies/hair-photobiomodulation/), [Lymphoedema: catching it early, and the operations for it](https://onco.cc/technologies/lymphoedema-surgery-and-early-detection/), [Massage therapy in cancer care](https://onco.cc/technologies/massage-therapy-cancer/), [Measuring fear of recurrence: the FCRI and its cut-off](https://onco.cc/technologies/rejuv-measure-fear-of-recurrence-inventory/), [Measuring lymphoedema: tape, bioimpedance and the quality of life scales](https://onco.cc/technologies/rejuv-measure-lymphoedema/), [Measuring memory and concentration after treatment](https://onco.cc/technologies/rejuv-measure-cognitive-function/), [Measuring muscle and fat on scans the patient already had](https://onco.cc/technologies/rejuv-measure-body-composition/), [Medicinal mushrooms: reishi, turkey tail, shiitake and others](https://onco.cc/technologies/medicinal-mushrooms-reishi-turkey-tail/), [Melatonin as a cancer adjunct](https://onco.cc/technologies/melatonin-cancer/), [Memory, attention and learning after treatment of a childhood cancer](https://onco.cc/technologies/rejuv-paed-neurocognitive/), [Menopause brought on by cancer treatment, and the options for it](https://onco.cc/technologies/menopause-after-cancer-treatment/), [Mesenchymal stromal cells for tissue damage](https://onco.cc/technologies/rejuv-frontier-mesenchymal-stromal-cells/), [Metformin as an anti-ageing drug after cancer](https://onco.cc/technologies/rejuv-frontier-metformin-ageing/), [Microbiome modulation to unlock immunotherapy](https://onco.cc/technologies/microbiome-modulation-io/), [Mindfulness-based stress reduction and cognitive therapy](https://onco.cc/technologies/mindfulness-based-interventions/), [Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss](https://onco.cc/technologies/minoxidil-chemotherapy-alopecia/), [Mistletoe extracts (Iscador, Helixor)](https://onco.cc/technologies/mistletoe-extracts/), [Money after treatment: what the cost of cancer does once the treatment has finished](https://onco.cc/technologies/rejuv-life-money-after-treatment/), [Muscle and strength after treatment: sarcopenia, cachexia and what rebuilds](https://onco.cc/technologies/muscle-recovery-after-cancer-treatment/), [Music therapy and music medicine](https://onco.cc/technologies/music-therapy-cancer/), [NAD+ precursors taken by mouth](https://onco.cc/technologies/rejuv-frontier-nad-precursors/), [Nails after chemotherapy: lifting, ridges and discolouration](https://onco.cc/technologies/nail-changes-after-chemotherapy/), [Nerve damage from chemotherapy: what recovers, and what helps](https://onco.cc/technologies/cipn-recovery-and-treatment/), [Nutrition support and cachexia management](https://onco.cc/technologies/oncology-nutrition/), [Oncofertility and fertility preservation](https://onco.cc/technologies/fertility-preservation/), [Oncology EHR modules and treatment pathways](https://onco.cc/technologies/hospital-information-systems-oncology/), [Oncology nursing and nurse-led care](https://onco.cc/technologies/oncology-nursing/), [Oncology nutrition assessment and medical nutrition therapy](https://onco.cc/technologies/nutrition-screening-mnt/), [Oncology pharmacy automation and compounding robots](https://onco.cc/technologies/pharmacy-automation/), [Oral cryotherapy (ice chips) to prevent mucositis](https://onco.cc/technologies/oral-cryotherapy-mucositis/), [Ovarian function after chemotherapy: who recovers, and when](https://onco.cc/technologies/ovarian-function-after-chemotherapy/), [Ozone therapy](https://onco.cc/technologies/rejuv-frontier-ozone-therapy/), [Palliative radiotherapy](https://onco.cc/technologies/palliative-radiotherapy/), [Partners and relationships after cancer: what the divorce data actually show](https://onco.cc/technologies/rejuv-life-partners-and-intimacy/), [Peer support and support groups](https://onco.cc/technologies/peer-support-groups/), [Pelvic floor rehabilitation after prostate and rectal surgery and after pelvic radiotherapy](https://onco.cc/technologies/rejuv-rehab-pelvic-floor/), [Pharmacogenomic testing before chemotherapy](https://onco.cc/technologies/oncology-pharmacogenomics/), [Photobiomodulation (low-level laser) for oral mucositis](https://onco.cc/technologies/photobiomodulation-mucositis/), [Platelet-rich plasma for hair after cancer treatment](https://onco.cc/technologies/hair-platelet-rich-plasma/), [Platelet-rich plasma for survivors](https://onco.cc/technologies/rejuv-frontier-platelet-rich-plasma/), [Post-traumatic growth: what people report, and what the measurement actually captures](https://onco.cc/technologies/rejuv-mind-post-traumatic-growth/), [Post-traumatic stress after cancer: what is measured, and how much of it is measurement](https://onco.cc/technologies/rejuv-mind-traumatic-stress-after-cancer/), [Prehabilitation before cancer surgery](https://onco.cc/technologies/prehabilitation/), [Preventing graft-versus-host disease, and what prevention costs](https://onco.cc/technologies/gvhd-prophylaxis/), [PRO-CTCAE: side effects graded by the person having them](https://onco.cc/technologies/rejuv-measure-pro-ctcae/), [Probiotics for chemotherapy and radiotherapy diarrhoea](https://onco.cc/technologies/probiotics-treatment-diarrhoea/), [Probiotics, antibiotics and stewardship around immunotherapy](https://onco.cc/technologies/probiotics-antibiotic-stewardship-io/), [PROMIS: the item banks that let a short questionnaire be precise](https://onco.cc/technologies/rejuv-measure-promis/), [Prospective surveillance: looking for the problem before it becomes a disability](https://onco.cc/technologies/rejuv-rehab-prospective-surveillance/), [Protecting the heart during anthracycline treatment: dexrazoxane, beta blockers and ACE inhibitors](https://onco.cc/technologies/anthracycline-cardioprotection/), [PSK (Krestin) mushroom polysaccharide as adjuvant therapy](https://onco.cc/technologies/psk-krestin-adjuvant/), [Psycho-oncology and distress screening](https://onco.cc/technologies/psycho-oncology/), [Quality of life after transplant and cell therapy](https://onco.cc/technologies/rejuv-tx-quality-of-life/), [Rapamycin and mTOR inhibition for ageing](https://onco.cc/technologies/rejuv-frontier-rapamycin-ageing/), [Rebuilding an immune system: the timeline, lineage by lineage](https://onco.cc/technologies/rejuv-tx-immune-reconstitution-timeline/), [Rebuilding the immune system after treatment](https://onco.cc/technologies/rejuv-frontier-immune-reconstitution/), [Referral to rehabilitation: the service most people who need it never see](https://onco.cc/technologies/rejuv-access-rehabilitation-referral/), [Reflexology](https://onco.cc/technologies/reflexology-cancer/), [Reiki, healing touch and other energy therapies](https://onco.cc/technologies/reiki-energy-therapies/), [Relaxation training and guided imagery](https://onco.cc/technologies/relaxation-guided-imagery/), [Resistance training and protein for cachexia and sarcopenia](https://onco.cc/technologies/resistance-training-cachexia/), [Revaccination after transplant: the schedules, and where the UK and the US differ](https://onco.cc/technologies/rejuv-tx-revaccination/), [Scalp care during and after cancer treatment](https://onco.cc/technologies/scalp-care-cancer-treatment/), [Scalp cooling (cold caps: DigniCap, Paxman)](https://onco.cc/technologies/scalp-cooling/), [Scars, stiffness and contracture: shoulders, necks and jaws](https://onco.cc/technologies/rejuv-rehab-scar-contracture/), [Scrambler therapy (Calmare) for chemotherapy nerve pain](https://onco.cc/technologies/scrambler-therapy/), [Screening for distress: what the thermometer can and cannot do](https://onco.cc/technologies/rejuv-mind-distress-screening/), [Second cancers after allogeneic transplant](https://onco.cc/technologies/rejuv-tx-second-cancers/), [Second cancers after childhood cancer: the risk by treatment, and why it is falling](https://onco.cc/technologies/rejuv-paed-second-cancers/), [Secondary T-cell malignancy after CAR-T, and what the FDA's 2024 action actually says](https://onco.cc/technologies/rejuv-tx-secondary-t-cell-malignancy/), [Senescent cells and p16 after chemotherapy](https://onco.cc/technologies/rejuv-age-senescent-cells-after-treatment/), [Senolytics after cancer treatment](https://onco.cc/technologies/rejuv-frontier-senolytics/), [Senolytics and senescence-directed therapy](https://onco.cc/technologies/senescence-targeting/), [Services built for teenagers and young adults, and what the national evaluation found](https://onco.cc/technologies/rejuv-ayac-services/), [Sexual function and intimacy after cancer, for both sexes](https://onco.cc/technologies/sexual-function-after-cancer/), [Shark cartilage (AE-941, Neovastat)](https://onco.cc/technologies/shark-cartilage/), [Skin during and after radiotherapy: dressings, steroids and what lasts](https://onco.cc/technologies/radiation-skin-recovery/), [Sleep after cancer: how common insomnia is, how long it lasts, and the treatment that works](https://onco.cc/technologies/rejuv-mind-sleep-after-cancer/), [Sleep and circadian interventions in cancer](https://onco.cc/technologies/sleep-circadian-interventions/), [Sleeping tablets after cancer: what they do and what they do not](https://onco.cc/technologies/rejuv-mind-sleeping-tablets-after-cancer/), [Smoking cessation in cancer patients](https://onco.cc/technologies/smoking-cessation-after-diagnosis/), [St John's wort: an interaction to avoid](https://onco.cc/technologies/st-johns-wort-interaction/), [Stem cell clinics and stem cell tourism](https://onco.cc/technologies/rejuv-frontier-stem-cell-tourism/), [Strain echocardiography (global longitudinal strain)](https://onco.cc/technologies/strain-echocardiography-gls/), [Structured exercise programmes after curative treatment](https://onco.cc/technologies/structured-exercise-survivorship/), [Supplements sold for hair growth after cancer treatment](https://onco.cc/technologies/hair-supplements-marketed/), [Survival after transplant, and why the curve never quite rejoins the population](https://onco.cc/technologies/rejuv-tx-survival-after-transplant/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/), [Swallowing therapy around head and neck radiotherapy](https://onco.cc/technologies/rejuv-rehab-swallowing/), [Tai chi and qigong](https://onco.cc/technologies/tai-chi-qigong/), [Teeth, jaws and facial growth after treatment in childhood](https://onco.cc/technologies/rejuv-paed-teeth-and-face/), [Telehealth and hospital-at-home in oncology](https://onco.cc/technologies/telehealth-oncology/), [Telemedicine, teleoncology, and telepathology](https://onco.cc/technologies/telemedicine-teleoncology/), [Telomere length after treatment](https://onco.cc/technologies/rejuv-age-telomere-length/), [Testosterone after cancer treatment in men](https://onco.cc/technologies/testosterone-after-cancer-treatment/), [The biological age test you can buy, and whether to buy one](https://onco.cc/technologies/rejuv-measure-consumer-biological-age-tests/), [The carer's own recovery: what is known about the person who is not the patient](https://onco.cc/technologies/rejuv-life-carers/), [The Children's Oncology Group Long-Term Follow-Up Guidelines](https://onco.cc/technologies/rejuv-paed-cog-ltfu-guidelines/), [The cumulative dose that decides whether it comes back](https://onco.cc/technologies/rejuv-recovery-cumulative-dose/), [The devices that do the restoring, and who pays for them](https://onco.cc/technologies/rejuv-rehab-assistive-devices/), [The exercise prescription after cancer: the dose the guidelines state](https://onco.cc/technologies/exercise-prescription-after-cancer/), [The gap between the rehabilitation people need and the rehabilitation they are offered](https://onco.cc/technologies/rejuv-rehab-provision-gap/), [The handover from children's to adult services, where follow-up falls away](https://onco.cc/technologies/rejuv-paed-transition-to-adult-care/), [The heart after anthracyclines and chest radiotherapy in childhood](https://onco.cc/technologies/rejuv-paed-heart/), [The lungs after transplant: bronchiolitis obliterans syndrome](https://onco.cc/technologies/gvhd-lung-bronchiolitis-obliterans/), [The pituitary, puberty and the hypothalamic axis after cranial radiotherapy in childhood](https://onco.cc/technologies/rejuv-paed-pituitary-and-puberty/), [The questionnaires that were never returned, and the people never asked](https://onco.cc/technologies/rejuv-measure-missing-data-and-who-is-not-asked/), [The word survivor, and why the vocabulary is not a detail](https://onco.cc/technologies/rejuv-mind-the-word-survivor/), [Thinking and memory after cancer treatment: what is measurable, and what helps](https://onco.cc/technologies/cognitive-impairment-after-cancer-treatment/), [TPMT and NUDT15 genotyping before thiopurines](https://onco.cc/technologies/tpmt-nudt15-genotyping/), [Traditional Chinese herbal medicine alongside treatment](https://onco.cc/technologies/traditional-chinese-herbal-medicine/), [Transfusion support and anaemia management](https://onco.cc/technologies/transfusion-support/), [Treating fear of recurrence: the randomised trials, their effect sizes, and where the treatment is available](https://onco.cc/technologies/rejuv-mind-fear-of-recurrence-treatment/), [Troponin and natriuretic peptide monitoring during cancer treatment](https://onco.cc/technologies/cardiac-biomarker-monitoring/), [UGT1A1 genotyping before irinotecan](https://onco.cc/technologies/ugt1a1-genotyping/), [Unlicensed peptides sold for recovery](https://onco.cc/technologies/rejuv-frontier-unlicensed-peptides/), [Vaginal oestrogen after breast cancer: what the evidence says, and where it disagrees](https://onco.cc/technologies/vaginal-oestrogen-after-breast-cancer/), [Voice after the larynx is removed](https://onco.cc/technologies/rejuv-recon-voice-after-laryngectomy/), [Walking, gripping and standing up: the tests that take five minutes](https://onco.cc/technologies/rejuv-measure-functional-tests/), [Wearables and step counts: measuring what someone actually does](https://onco.cc/technologies/rejuv-measure-wearables-and-step-counts/), [What a difference has to be before a person would notice it](https://onco.cc/technologies/rejuv-measure-minimally-important-difference/), [What actually works after treatment](https://onco.cc/technologies/rejuv-frontier-what-works/), [What comes back after treatment, treatment by treatment](https://onco.cc/technologies/rejuv-recovery-matrix/), [What has actually been implemented since those trials, and what has not](https://onco.cc/technologies/rejuv-measure-epro-implementation/), [What recovery costs in the rest of the world](https://onco.cc/technologies/rejuv-access-what-it-costs-elsewhere/), [What recovery costs in the UK, and what it does not](https://onco.cc/technologies/rejuv-access-what-it-costs-uk/), [What recovery costs in the United States](https://onco.cc/technologies/rejuv-access-what-it-costs-us/), [What the randomised trials of prehabilitation found, operation by operation](https://onco.cc/technologies/rejuv-rehab-prehabilitation-evidence/), [When steroids fail: ruxolitinib for steroid-refractory GvHD](https://onco.cc/technologies/gvhd-ruxolitinib-steroid-refractory/), [Where rehabilitation is commissioned, and who misses out](https://onco.cc/technologies/rejuv-rehab-commissioning-inequity/), [Who gets told about fertility before treatment, and who does not](https://onco.cc/technologies/rejuv-access-fertility-preservation/), [Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered](https://onco.cc/technologies/rejuv-tx-long-term-follow-up-frameworks/), [Who misses out on recovery care, measured](https://onco.cc/technologies/rejuv-access-who-misses-out/), [Wigs, cranial prostheses and head coverings](https://onco.cc/technologies/wigs-cranial-prosthesis/), [Yoga during and after cancer treatment](https://onco.cc/technologies/yoga-cancer/)
- companies: [Acacia Pharma](https://onco.cc/companies/acacia-pharma/), [Angiocrine Bioscience](https://onco.cc/companies/angiocrine-bioscience/), [B. Braun](https://onco.cc/companies/b-braun/), [Baxter International](https://onco.cc/companies/baxter/), [Belong.Life](https://onco.cc/companies/belong-life/), [BeyondSpring Pharmaceuticals](https://onco.cc/companies/beyondspring/), [BioLineRx](https://onco.cc/companies/biolinerx/), [Cancer Commons](https://onco.cc/companies/cancer-commons/), [Canopy](https://onco.cc/companies/canopy/), [Careology](https://onco.cc/companies/careology/), [Carevive Systems](https://onco.cc/companies/carevive-systems/), [Carrum Health](https://onco.cc/companies/carrum-health/), [Changchun GeneScience Pharmaceutical](https://onco.cc/companies/changchun-genescience/), [Color Health](https://onco.cc/companies/color-health/), [CSL Limited](https://onco.cc/companies/csl/), [Florida Cancer Specialists & Research Institute](https://onco.cc/companies/florida-cancer-specialists/), [G1 Therapeutics](https://onco.cc/companies/g1-therapeutics/), [Galera Therapeutics](https://onco.cc/companies/galera-therapeutics/), [Grifols](https://onco.cc/companies/grifols/), [Insys Therapeutics](https://onco.cc/companies/insys-therapeutics/), [Intas Pharmaceuticals (Accord Healthcare)](https://onco.cc/companies/intas/), [Jasper Health](https://onco.cc/companies/jasper-health/), [JW Pharmaceutical](https://onco.cc/companies/jw-pharmaceutical/), [Kaiku Health (Elekta)](https://onco.cc/companies/kaiku-health/), [Kanvas Biosciences](https://onco.cc/companies/kanvas-biosciences/), [Liyfe](https://onco.cc/companies/liyfe/), [Luminate Medical](https://onco.cc/companies/luminate-medical/), [MaaT Pharma](https://onco.cc/companies/maat-pharma/), [McKesson / The US Oncology Network](https://onco.cc/companies/mckesson-us-oncology/), [Mednet (theMednet)](https://onco.cc/companies/mednet/), [Mesoblast](https://onco.cc/companies/mesoblast/), [Monopar Therapeutics](https://onco.cc/companies/monopar/), [MORE Health](https://onco.cc/companies/more-health/), [Mundipharma](https://onco.cc/companies/mundipharma/), [Navexio](https://onco.cc/companies/navexio/), [Omanta](https://onco.cc/companies/omanta/), [Omnicell](https://onco.cc/companies/omnicell/), [OncoHealth](https://onco.cc/companies/oncohealth/), [OneOncology](https://onco.cc/companies/oneoncology/), [Osara Health](https://onco.cc/companies/osara-health/), [Outcomes4Me](https://onco.cc/companies/outcomes4me/), [Partner Therapeutics](https://onco.cc/companies/partner-therapeutics/), [Patient Data Vault (data-vault.health)](https://onco.cc/companies/patient-data-vault/), [Perci Health](https://onco.cc/companies/perci-health/), [Pharmacosmos](https://onco.cc/companies/pharmacosmos/), [Reimagine Care](https://onco.cc/companies/reimagine-care/), [REPROSENT](https://onco.cc/companies/reprosent/), [Rovi](https://onco.cc/companies/rovi/), [Sarah Cannon Research Institute](https://onco.cc/companies/sarah-cannon-research-institute/), [Sorrento Therapeutics](https://onco.cc/companies/sorrento-therapeutics/), [Spectrum Pharmaceuticals](https://onco.cc/companies/spectrum-pharmaceuticals/), [TailorMed](https://onco.cc/companies/tailormed/), [Thyme Care](https://onco.cc/companies/thyme-care/), [Triomics](https://onco.cc/companies/triomics/), [Wuhan YZY Biopharma](https://onco.cc/companies/wuhan-yzy-biopharma/)
- journals: [Supportive care in cancer](https://onco.cc/journals/supportive-care-in-cancer/)
- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- key papers: [Association of Black race with prostate cancer-specific and other-cause mortality](https://onco.cc/key-papers/paper-dess-black-race-prostate-mortality-jama-oncol-2019/), [Basch: asking patients to report symptoms online during chemotherapy improved survival](https://onco.cc/key-papers/paper-basch-epro-survival-jama-2017/), [Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease](https://onco.cc/key-papers/paper-travis-breast-cancer-after-hodgkin-radiotherapy-jama-2003/), [Burosumab for the treatment of tumor-induced osteomalacia (UX023T-CL201)](https://onco.cc/key-papers/paper-ux023t-cl201-jan-de-beur-jbmr-2021/), [Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk](https://onco.cc/key-papers/paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015/), [CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer](https://onco.cc/key-papers/paper-challenge-exercise-nejm-2025/), [Efficacy and safety of lipegfilgrastim versus pegfilgrastim in breast cancer patients receiving doxorubicin and docetaxel (XM22-03)](https://onco.cc/key-papers/paper-xm22-03-bondarenko-bmc-cancer-2013/), [Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity](https://onco.cc/key-papers/paper-vistogard-cancer-2017/), [Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study](https://onco.cc/key-papers/paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019/), [Epoetin theta with a new dosing schedule in anaemic cancer patients receiving nonplatinum-based chemotherapy: a randomised controlled trial (XM01-22)](https://onco.cc/key-papers/paper-xm01-22-tjulandin-arch-drug-inf-2011/), [GAP70+: a geriatric assessment before chemotherapy cut serious toxicity in older adults by a fifth](https://onco.cc/key-papers/paper-gap70-geriatric-assessment-lancet-2021/), [Methylnaltrexone for opioid-induced constipation in advanced illness (MNTX 302)](https://onco.cc/key-papers/paper-mntx-302-thomas-nejm-2008/), [Ponsegromab for the Treatment of Cancer Cachexia](https://onco.cc/key-papers/paper-groarke-ponsegromab-cancer-cachexia-nejm-2024/), [Preservation of the pylorus in pancreaticoduodenectomy](https://onco.cc/key-papers/paper-traverso-longmire-pylorus-preservation-pancreaticoduodenectomy-sgo-1978/), [Rolapitant for prevention of chemotherapy-induced nausea and vomiting after moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens: a randomised, active-controlled, double-blind, phase 3 trial](https://onco.cc/key-papers/paper-rolapitant-study-3-schwartzberg-lancet-oncol-2015/), [Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma](https://onco.cc/key-papers/paper-schaapveld-second-cancer-risk-40-years-hodgkin-nejm-2015/), [Setmelanotide for the treatment of acquired hypothalamic obesity (TRANSCEND)](https://onco.cc/key-papers/paper-transcend-miller-nejm-2026/), [SWOG 9346: intermittent versus continuous androgen deprivation in metastatic prostate cancer](https://onco.cc/key-papers/paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013/), [Temel: early palliative care alongside chemotherapy improved quality of life, mood and survival in lung cancer](https://onco.cc/key-papers/paper-temel-early-palliative-care-nejm-2010/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/), [Recovery and rejuvenation roadmap: cure is not enough → survivorship gets a name → the cohorts that measured the cost → exercise proven as treatment → biological ageing measured and sold → repair, if anyone funds it](https://onco.cc/roadmaps/rejuvenation-roadmap/), [Supportive care and survivorship roadmap: making treatment bearable → proving it extends life → caring for tens of millions afterwards](https://onco.cc/roadmaps/survivorship-roadmap/)
- ideas: [A dietitian in every gastrointestinal and head and neck tumour board](https://onco.cc/ideas/idea-nl-dietitian-in-every-mdt/), [A risk-stratified cardio-oncology pathway for everyone receiving heart-toxic cancer therapy](https://onco.cc/ideas/idea-acc-risk-stratified-cardio-oncology-pathway/), [Acute oncology assessment units so sick cancer patients bypass the emergency department](https://onco.cc/ideas/idea-acc-acute-oncology-assessment-units/), [Agree what to measure, so the next systematic review can pool rather than narrate](https://onco.cc/ideas/idea-rejuv-core-outcome-set-for-late-effects/), [Ask about diet at diagnosis, and prebunk the myths before the internet does](https://onco.cc/ideas/idea-nl-ask-about-diet-prebunking/), [Ask whether survivorship screening saves lives, using registry-based randomisation](https://onco.cc/ideas/idea-rejuv-registry-randomised-screening-in-survivors/), [Automatic palliative care referral triggered by diagnosis, not by decline](https://onco.cc/ideas/idea-acc-automatic-early-palliative-triggers/), [Caregiver training and respite as a covered service in cancer care for older patients](https://onco.cc/ideas/idea-acc-caregiver-training-as-covered-service/), [Confirm or refute the harm of antioxidant supplements during chemotherapy](https://onco.cc/ideas/idea-nl-antioxidant-supplement-harm-confirmation/), [Default fertility preservation referral for every patient under 40 before treatment](https://onco.cc/ideas/idea-acc-default-fertility-preservation-referral/), [Embed cachexia treatment in chemotherapy trials: weight, muscle and treatment delivery as co-primary endpoints](https://onco.cc/ideas/idea-pdac-cachexia-trials-embedded-in-chemotherapy-trials/), [Enrol every new systemic therapy into a registry linkage that will still report in thirty years](https://onco.cc/ideas/idea-rejuv-second-cancer-latency-cohort-for-new-drugs/), [Find out whether an adult thymus can be made to work again, with an endpoint a clinician would act on](https://onco.cc/ideas/idea-rejuv-thymic-regeneration-in-adults/), [Fund structured exercise after colon cancer surgery as a treatment, because a randomised trial says it works as well as a drug](https://onco.cc/ideas/idea-crc-exercise-as-a-funded-treatment/), [Geriatric assessment by default for every patient over 70 starting cancer treatment](https://onco.cc/ideas/idea-acc-geriatric-assessment-by-default/), [Give survivorship interventions a shared control arm](https://onco.cc/ideas/idea-rejuv-survivorship-platform-trial/), [Hospital-at-home for oncology: treating low-risk febrile neutropenia and dehydration at home](https://onco.cc/ideas/idea-acc-hospital-at-home-oncology/), [Make early palliative care and a goals conversation part of every advanced-cancer pathway](https://onco.cc/ideas/idea-cost-early-palliative-default/), [Make the treatment exposure record machine-readable, so surveillance can be computed](https://onco.cc/ideas/idea-rejuv-exposure-record-a-machine-can-read/), [Measure and publish pain control rates in every cancer centre](https://onco.cc/ideas/idea-acc-pain-control-public-audit/), [Measure the late effects of the treatments being given now, not the ones given in 1975](https://onco.cc/ideas/lymphoma-ev-late-effects-of-the-treatments-given-now/), [Oncology pharmacists as protocol prescribers for supportive care and dose adjustments](https://onco.cc/ideas/idea-acc-oncology-pharmacist-prescribing/), [Pancreatic enzyme replacement by default: prescribe at diagnosis, audit the rate, and run the trial that settles survival](https://onco.cc/ideas/idea-pdac-enzyme-replacement-prescribing-by-default/), [Patient-reported symptoms captured as standard structured data in every clinic](https://onco.cc/ideas/idea-data-pro-as-structured-standard/), [Prospective arm-volume surveillance to catch and reverse lymphoedema early](https://onco.cc/ideas/idea-acc-lymphoedema-prospective-surveillance/), [Put a biological-age marker in a trial that also measures something a person would notice](https://onco.cc/ideas/idea-rejuv-biological-age-as-a-randomised-endpoint/), [Raise the share of UK patients who receive any active treatment, and publish it by trust](https://onco.cc/ideas/idea-pdac-uk-active-treatment-rate-audit-and-target/), [Report death from other causes as an outcome of the prostate cancer service, split by deprivation and ethnicity](https://onco.cc/ideas/idea-prostate-other-cause-mortality-as-a-reported-service-outcome/), [Structured deprescribing review at cancer diagnosis and again at transition to palliative care](https://onco.cc/ideas/idea-acc-structured-deprescribing-at-diagnosis/), [The drugs that cure lymphoma, and the places that do not have them](https://onco.cc/ideas/lymphoma-ev-the-drugs-that-cure-and-the-places-without-them/), [Toxicity-management decision support for nurses and pharmacists](https://onco.cc/ideas/idea-data-toxicity-cds-for-nurses/), [Train every oncology team in serious-illness conversations and prompt them in the record](https://onco.cc/ideas/idea-acc-serious-illness-conversation-prompts/), [Treat insomnia in survivors and measure whether the cancer notices](https://onco.cc/ideas/idea-nl-sleep-circadian-survivorship-rct/), [Wearable activity data as a validated real-world endpoint](https://onco.cc/ideas/idea-data-wearable-endpoints-validation/), [Weekly electronic symptom reporting as a standard of care during systemic therapy](https://onco.cc/ideas/idea-acc-electronic-pro-monitoring-standard/), [Write a rehabilitation prescription at the end of treatment, and fund it like a drug](https://onco.cc/ideas/idea-rejuv-rehabilitation-prescription-at-discharge/)
- terms: [Age, smoking and inherited predisposition: what the treatment risk is added to](https://onco.cc/terms/rejuv-second-age-smoking-and-inherited-risk/), [Alkylating agents and therapy-related myeloid neoplasms](https://onco.cc/terms/rejuv-second-alkylating-agents-and-myeloid-neoplasms/), [Anaemia](https://onco.cc/terms/anaemia/), [Anagen effluvium (chemotherapy hair loss)](https://onco.cc/terms/hair-anagen-effluvium/), [Anti-VEGF class toxicities (hypertension, proteinuria, bleeding, perforation)](https://onco.cc/terms/antiangiogenic-toxicities/), [Bladder cancer after cyclophosphamide](https://onco.cc/terms/second-primary-bladder-after-cyclophosphamide/), [Bone metastases and skeletal-related events](https://onco.cc/terms/bone-metastases/), [Bowel cancer after abdominal and pelvic radiotherapy](https://onco.cc/terms/second-primary-bowel-after-abdominal-radiotherapy/), [Breast cancer after chest radiotherapy given young](https://onco.cc/terms/second-primary-breast-after-chest-radiotherapy/), [Cardiotoxicity (LVEF decline, cardiomyopathy)](https://onco.cc/terms/cardiotoxicity/), [Central venous access (port, PICC line)](https://onco.cc/terms/central-venous-access/), [Choices made at the time of treatment that change the second cancer risk](https://onco.cc/terms/rejuv-second-choices-made-at-treatment/), [Counting the people who live after cancer, and why the number is not a detail](https://onco.cc/terms/rejuv-history-counting-survivors/), [CTCAE toxicity grading (grade 3-4 adverse events)](https://onco.cc/terms/ctcae-grading/), [Curative intent vs palliative intent](https://onco.cc/terms/curative-intent/), [Cure is not enough: when late effects stopped being an afterthought](https://onco.cc/terms/rejuv-history-cure-is-not-enough/), [Cytopenias and myelosuppression](https://onco.cc/terms/cytopenias/), [Dose reduction, interruption and discontinuation](https://onco.cc/terms/dose-modification/), [Dysphagia (difficulty swallowing)](https://onco.cc/terms/dysphagia/), [Endocrine-therapy-induced alopecia](https://onco.cc/terms/alopecia-endocrine-therapy/), [Eyebrow and eyelash loss (madarosis)](https://onco.cc/terms/hair-brows-and-lashes/), [Febrile neutropenia](https://onco.cc/terms/febrile-neutropenia/), [Feeding tube (gastrostomy, PEG, jejunostomy)](https://onco.cc/terms/feeding-tube/), [From a clone in the blood to a leukaemia: what is known, and what is done](https://onco.cc/terms/rejuv-second-from-clone-to-disease/), [Hand-foot syndrome and hand-foot skin reaction](https://onco.cc/terms/hand-foot-syndrome/), [Hepatotoxicity (liver enzyme elevation)](https://onco.cc/terms/hepatotoxicity/), [Hyperglycaemia (PI3K/AKT inhibitor class effect)](https://onco.cc/terms/hyperglycaemia/), [Hypogammaglobulinaemia and infection risk after B-cell therapies](https://onco.cc/terms/hypogammaglobulinaemia/), [Immune-mediated colitis and diarrhoea](https://onco.cc/terms/immune-colitis/), [Immune-related endocrinopathies (thyroiditis, hypophysitis)](https://onco.cc/terms/immune-endocrinopathy/), [Immune-related myocarditis](https://onco.cc/terms/myocarditis/), [Infusion reactions, hypersensitivity and extravasation](https://onco.cc/terms/extravasation-infusion-reaction/), [Intermittent androgen deprivation (IAD)](https://onco.cc/terms/intermittent-androgen-deprivation/), [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/), [Lost in Transition: the 2006 report that defined survivorship care, and the care plan it invented](https://onco.cc/terms/rejuv-history-lost-in-transition/), [Lung cancer after chest radiotherapy and after alkylating chemotherapy](https://onco.cc/terms/second-primary-lung-after-chest-radiotherapy/), [Malignant pleural effusion and ascites](https://onco.cc/terms/pleural-effusion/), [Mucositis and stomatitis](https://onco.cc/terms/mucositis/), [Neutropenia](https://onco.cc/terms/neutropenia/), [Obstructive jaundice and biliary obstruction](https://onco.cc/terms/obstructive-jaundice/), [Ocular toxicity (keratopathy, blurred vision)](https://onco.cc/terms/ocular-toxicity/), [Other-cause mortality](https://onco.cc/terms/other-cause-mortality/), [Performance status (ECOG, Karnofsky)](https://onco.cc/terms/performance-status/), [Peripheral neuropathy (chemotherapy-induced)](https://onco.cc/terms/peripheral-neuropathy/), [Persistent chemotherapy-induced alopecia](https://onco.cc/terms/alopecia-persistent-chemotherapy/), [Persistent radiation-induced alopecia](https://onco.cc/terms/alopecia-radiotherapy-persistent/), [Platinum drugs and PARP inhibitors: the newer leukaemia risk](https://onco.cc/terms/rejuv-second-platinum-and-parp-inhibitors/), [Pleurodesis and indwelling pleural catheter](https://onco.cc/terms/pleurodesis/), [QT prolongation](https://onco.cc/terms/qt-prolongation/), [Quality of life and patient-reported outcomes (QoL, PRO)](https://onco.cc/terms/qol-pro/), [Radiotherapy and second cancers: field, dose and age at exposure](https://onco.cc/terms/rejuv-second-radiotherapy-dose-field-and-age/), [Rash and skin toxicity (acneiform rash, paronychia)](https://onco.cc/terms/rash-skin-toxicity/), [Regrowth after chemotherapy (chemo curls)](https://onco.cc/terms/hair-regrowth-after-chemotherapy/), [Sarcoma in the radiotherapy field, and angiosarcoma of the treated breast](https://onco.cc/terms/second-primary-sarcoma-in-the-treated-field/), [Screening survivors: where the UK, American and European answers differ](https://onco.cc/terms/rejuv-second-screening-after-treatment-compared/), [Seasons of Survival: the 1985 essay that named the problem](https://onco.cc/terms/rejuv-history-seasons-of-survival/), [Second cancers after treatment: what the risk is, and what is done about it](https://onco.cc/terms/rejuv-second-cancers-overview/), [Secondary malignancy (therapy-related cancer)](https://onco.cc/terms/secondary-malignancy/), [Skin cancer after cancer treatment](https://onco.cc/terms/second-primary-skin-cancer-after-cancer-treatment/), [Stenting (biliary, oesophageal, airway)](https://onco.cc/terms/biliary-stent/), [Stoma (colostomy, ileostomy, urostomy)](https://onco.cc/terms/stoma/), [The founding of the National Coalition for Cancer Survivorship, and the word survivor](https://onco.cc/terms/rejuv-history-survivorship-movement/), [The National Cancer Survivorship Initiative in England, and the Recovery Package](https://onco.cc/terms/rejuv-history-ncsi-england/), [The scar on the face after skin cancer surgery](https://onco.cc/terms/facial-scar-after-skin-cancer/), [The UK very high risk breast screening protocol after chest radiotherapy](https://onco.cc/terms/rejuv-second-uk-very-high-risk-breast-screening/), [Thrombocytopenia](https://onco.cc/terms/thrombocytopenia/), [Thyroid cancer after neck radiotherapy, and whether to look for it](https://onco.cc/terms/second-primary-thyroid-after-neck-radiotherapy/), [Topoisomerase II inhibitors and the shorter latency](https://onco.cc/terms/rejuv-second-topoisomerase-inhibitors-short-latency/), [Venous thromboembolism (VTE)](https://onco.cc/terms/vte/), [What is not a second cancer: recurrence, metastasis and field cancerisation](https://onco.cc/terms/rejuv-second-what-is-not-a-second-cancer/)
- drugs: [Eltrombopag](https://onco.cc/drugs/eltrombopag/), [Emapalumab](https://onco.cc/drugs/emapalumab/), [Fostamatinib](https://onco.cc/drugs/fostamatinib/), [Propranolol (Hemangeol)](https://onco.cc/drugs/propranolol-hemangeol/), [Ravulizumab](https://onco.cc/drugs/ravulizumab/), [Remestemcel-L](https://onco.cc/drugs/remestemcel-l/), [Romiplostim](https://onco.cc/drugs/romiplostim/)
- people: [Dame Cicely Saunders](https://onco.cc/people/cicely-saunders/), [Elisabeth Kübler-Ross](https://onco.cc/people/elisabeth-kubler-ross/), [Ellen L. Stovall](https://onco.cc/people/ellen-stovall/), [Fitzhugh Mullan](https://onco.cc/people/fitzhugh-mullan/), [Jimmie Holland](https://onco.cc/people/jimmie-holland/), [Tobias Janowitz](https://onco.cc/people/tobias-janowitz/)
- bottlenecks: [Cachexia, toxicity and the limits of the patient](https://onco.cc/bottlenecks/b-cachexia-supportive/), [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [No randomised trial shows that any survivorship screening programme reduces death](https://onco.cc/bottlenecks/rejuv-agenda-screening-without-a-trial/), [No treatment restores the thinking that cancer treatment takes](https://onco.cc/bottlenecks/rejuv-agenda-nothing-restores-cognition/), [Nobody has tested whether reversing measured biological ageing changes anything](https://onco.cc/bottlenecks/rejuv-agenda-biological-age-as-an-untested-target/), [Nobody owns the follow-up once the oncology clinic lets go](https://onco.cc/bottlenecks/rejuv-agenda-nobody-owns-the-follow-up/), [Nothing in routine use rebuilds an adult's thymus](https://onco.cc/bottlenecks/rejuv-agenda-thymus-does-not-regrow/), [Pain relief and palliative care are unavailable to most](https://onco.cc/bottlenecks/b-palliative/), [Registries count diagnoses and deaths, and not what treatment left behind](https://onco.cc/bottlenecks/rejuv-agenda-late-effects-are-not-counted/), [Rehabilitation is recommended everywhere and commissioned almost nowhere](https://onco.cc/bottlenecks/rejuv-agenda-rehabilitation-not-commissioned/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [The field cannot pool its own studies, because it has not agreed what to measure](https://onco.cc/bottlenecks/rejuv-agenda-no-agreed-outcome-measures/), [The newest treatments have not existed long enough for their late effects to appear](https://onco.cc/bottlenecks/rejuv-agenda-latency-outruns-the-evidence/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)
- trials: [AlloCare: a stepped-care late-effects service after allogeneic transplant](https://onco.cc/trials/rejuv-trial-allocare/), [AMICO: aerobic or resistance exercise to improve outcome in metastatic colorectal cancer](https://onco.cc/trials/rejuv-trial-amico/), [CanWork: an occupational therapy programme to help women return to work after breast cancer](https://onco.cc/trials/rejuv-trial-canwork/), [Childhood Cancer Survivor Study (CCSS)](https://onco.cc/trials/ccss/), [EX-CIPN: virtual exercise-based rehabilitation for persistent chemotherapy nerve damage](https://onco.cc/trials/rejuv-trial-ex-cipn/), [Low-dose olanzapine for cancer anorexia (Tata Memorial)](https://onco.cc/trials/olanzapine-appetite-tmh/), [MNTX 302](https://onco.cc/trials/mntx-302/), [Ponsegromab phase 2 in cancer cachexia](https://onco.cc/trials/ponsegromab-phase-2/), [PROFFi: fisetin and exercise to prevent frailty in breast cancer survivors](https://onco.cc/trials/rejuv-trial-proffi/), [ROMANA 1 and ROMANA 2](https://onco.cc/trials/romana-1-2/), [Study 3 (rolapitant, moderately emetogenic chemotherapy)](https://onco.cc/trials/ts-p04834/), [Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer](https://onco.cc/trials/nct03937154/), [TRANSCEND](https://onco.cc/trials/transcend/), [UX023T-CL201](https://onco.cc/trials/ux023t-cl201/), [Vistogard Studies 1 and 2](https://onco.cc/trials/vistogard-studies-1-2/), [XM01-22](https://onco.cc/trials/xm01-22/), [XM22-03](https://onco.cc/trials/xm22-03/)
- institutions: [Atrium Health Wake Forest Baptist Comprehensive Cancer Center](https://onco.cc/institutions/wake-forest-cancer/), [Butaro Cancer Center of Excellence](https://onco.cc/institutions/butaro-cancer-center/), [Canadian Cancer Society](https://onco.cc/institutions/canadian-cancer-society/), [Children's Cancer Hospital Egypt 57357](https://onco.cc/institutions/cche-57357/), [Chris O'Brien Lifehouse](https://onco.cc/institutions/chris-obrien-lifehouse/), [Christian Medical College, Vellore](https://onco.cc/institutions/cmc-vellore/), [Deutsche Krebsgesellschaft](https://onco.cc/institutions/deutsche-krebsgesellschaft/), [European Cancer Organisation](https://onco.cc/institutions/ecco/), [European Society for Clinical Nutrition and Metabolism](https://onco.cc/institutions/espen/), [Instituto Português de Oncologia de Lisboa Francisco Gentil](https://onco.cc/institutions/ipo-lisboa/), [International Society for Quality of Life Research](https://onco.cc/institutions/isoqol/), [Irish Cancer Society](https://onco.cc/institutions/irish-cancer-society/), [Israel Cancer Association](https://onco.cc/institutions/israel-cancer-association/), [Koo Foundation Sun Yat-Sen Cancer Center](https://onco.cc/institutions/koo-foundation-sun-yat-sen-cancer-center/), [Ligue nationale contre le cancer](https://onco.cc/institutions/ligue-contre-le-cancer/), [Macmillan Cancer Support](https://onco.cc/institutions/macmillan-cancer-support/), [Marie Curie](https://onco.cc/institutions/marie-curie-uk/), [Movember](https://onco.cc/institutions/movember/), [Multinational Association of Supportive Care in Cancer](https://onco.cc/institutions/mascc/), [National Cancer Grid of India](https://onco.cc/institutions/national-cancer-grid/), [National Health Authority (Ayushman Bharat PM-JAY)](https://onco.cc/institutions/nha-pmjay/), [Olivia Newton-John Cancer Wellness and Research Centre](https://onco.cc/institutions/onj-cancer-centre/), [Organisation of European Cancer Institutes](https://onco.cc/institutions/oeci/), [Shaare Zedek Medical Center](https://onco.cc/institutions/shaare-zedek/), [Wilmot Cancer Institute, University of Rochester](https://onco.cc/institutions/wilmot/)
- collections: [British Childhood Cancer Survivor Study (BCCSS)](https://onco.cc/collections/bccss/), [International Guideline Harmonization Group for late effects of childhood cancer](https://onco.cc/collections/ighg/), [PanCareSurFup and the European survivor cohorts](https://onco.cc/collections/pancaresurfup/), [St Jude Lifetime Cohort Study (SJLIFE)](https://onco.cc/collections/sjlife/)

---
JSON: https://onco.cc/api/v1/entities/supportive-care.json